

February 14, 2022

CURRICULUM VITAE

Name: Boris Freidlin

Office Address:

Biostatistics Branch
Biometric Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
9609 Medical Center Drive, Room 5W102 MSC9735
Bethesda, MD 20892-9735
(240) 276 - 6024 (office)
(240) 276 - 7888 (fax)
freidlinb@ctep.nci.nih.gov

Education:

1998	Ph.D., Statistics George Washington University, Washington, DC
1992	M.S., Applied Statistics George Washington University, Washington, DC
1988	B.S., Mathematics University of Maryland, College Park, MD

Professional Experience:

2019-present	<i>Branch Chief</i> , Biostatistics Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
1998-2019	<i>Mathematical Statistician</i> , Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
1993-1998	<i>Statistician</i> , The EMMES Corporation, Potomac, MD
1992-1993	<i>Statistician</i> , Synectics, Arlington, VA
1989-1992	<i>Research Assistant</i> , GWU Biostatistics Center, Rockville, MD

Selected Professional Activities:

Associate editor: *Clinical Trials*

Referee for *American Journal of Epidemiology*, *Annals of Oncology*, *Biometrical Journal*, *Biometrics*, *Biometrika*, *Clinical Cancer Research*, *Clinical Trials*, *Journal of Clinical Oncology*, *Journal of the National Cancer Institute*, *Nature Reviews Clinical Oncology*, *Pharmaceutical Statistics* and *Statistics in Medicine*.

Awards:

American Statistical Association Outstanding Statistical Application Award (2002).

Professional Societies:

American Statistical Association

Publications:

1. Trimble E, Carter C, Cain D, **Freidlin B**, Ungerleider R, Friedman M. Representation of older patients in cancer treatment trials. *Cancer Supplement* 74:2208-2214, 1994
2. Pompetti F, Rizzo P, Simon R, **Freidlin B**, Mew D, Pass H, Picci P, Levine A, Carbone M. Oncogene alterations in primary, recurrent and metastatic human bone tumors. *Journal of Cellular Biochemistry* 63:37-50, 1996
3. Simon R, **Freidlin B**, Rubinstein L, Arbuck S, Collins J, Christian M. Accelerated titration designs for phase I clinical trials in oncology. *Journal of the National Cancer Institute* 89:1138-1147, 1997
4. Becker KG, Simon RM, Bailey-Wilson J, **Freidlin B**, Biddison W, McFarland H, Trent J. Clustering of non-MHC susceptibility candidate loci in human autoimmune diseases. *Proceedings of National Academy of Science* 17:9979-9984, 1998
5. Smith M, **Freidlin B**, Gloeckler Reis LA, Simon R. Trends in the reported incidence of primary malignant brain tumors in children in the United States. *Journal of the National Cancer Institute* 90:1269-1277, 1998
6. **Freidlin B**, Gastwirth JL. Unconditional versions of several tests commonly used in the analysis of contingency tables. *Biometrics* 55:84-89, 1999

7. Smith M, Rubinstein L, Anderson J, Arthur D, Catalano PP, **Freidlin B**, Heyn, R, Khayat A, Krailo M, Land V, Miser J, Shuster J, Vena D. Secondary leukemia or myelodysplastic syndrome following treatment with epipodophyllotoxins. *Journal of Clinical Oncology* 17:569-577, 1999
8. **Freidlin B**, Podgor MJ, and Gastwirth, JL. Efficiency robust tests for survival and ordered categorical data. *Biometrics* 55:883-886, 1999
9. **Freidlin B**, Korn EL, George SL. Data monitoring committees and interim monitoring guidelines. *Controlled Clinical Trials* 20:395-407, 1999
10. Cheson BD, Vena DA, Barrett J, **Freidlin B**. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. *Journal of Clinical Oncology* 17:2454-2460, 1999
11. Bublely GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, **Freidlin B**, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. *Journal of Clinical Oncology* 17: 3461-3467, 1999
12. **Freidlin B**, Gastwirth JL. Should the median test be retired from the general use? *American Statistician* 54:161-164, 2000
13. Gastwirth, JL, **Freidlin B**. On power and efficiency robust linkage tests for affected sibs. *Annals of Human Genetics*, 64:443-453, 2000
14. **Freidlin B**, Gastwirth JL. Changepoint tests designed for the analysis of hiring data arising in employment discrimination cases. *Journal of Business and Economic Statistics* 18:315-322, 2000
15. Breathnach OS, **Freidlin B**, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. *Journal of Clinical Oncology* 19(6):1734-1742, 2001
16. **Freidlin B**, Korn EL. A testing procedure for survival data with few responders. *Statistics in Medicine* 21:65-78, 2002
17. **Freidlin B**, Dancey J, Korn EL, Zee B, and Eisenhauer E. Multinomial phase II trial designs (letter). *Journal of Clinical Oncology* 20:599, 2002
18. Zheng G, **Freidlin B**, Gastwirth JL. Robust TDT-type candidate gene association tests. *Annals of Human Genetics* 66:145-155, 2002
19. **Freidlin B** and Korn EL. A comment on futility monitoring. *Controlled Clinical Trials* 23:355-356, 2002

20. **Freidlin B**, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. *Human Heredity*, 53:146-152, 2002
21. Jane PA, **Freidlin B**, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America - Meaningful improvements in survival. *Cancer* 95, 1528-1538, 2002
22. McShane LM, Radmacher MD, **Freidlin B**, et al. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. *Bioinformatics* 18:1462-1469, 2002
23. **Freidlin B**, Breathnach OS, Johnson BE. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. *Clinical Cancer Research* 9:917-922, 2003
24. Zheng G, **Freidlin B**, Li ZH, Gastwirth JL. Choice of scores in trend tests for case-control studies of candidate-gene associations. *Biometrical Journal* 45:335-348, 2003
25. Dancy JE, **Freidlin B**. Targeting epidermal growth factor receptor - are we missing the mark? *Lancet* 362:62-64, 2003
26. **Freidlin B**, Zheng G, Li ZH, Gastwirth JL. Efficiency robust tests for mapping quantitative trait loci using extremely discordant sib pairs. *Human Heredity* 55:117-124, 2003
27. **Freidlin B**, Miao W, Gastwirth JL. On the use of the Shapiro-Wilk test in two-stage adaptive inference for paired data from moderate to very heavy tailed distributions. *Biometrical Journal* 45:887-900, 2003
28. **Freidlin B**, Korn EL. Erythropoietin to treat anemia in patients with head and neck cancer (letter). *Lancet* 363:81, 2004
29. Korn EL, **Freidlin B**, Gorge SL. Data monitoring and large apparent treatment effects (letter). *Controlled Clinical Trials* 25:67-69, 2004
30. **Freidlin B**, Korn EL. A testing procedure for survival data with few responders (letter) *Statistics in Medicine* 23:1818-1823, 2004
31. Zheng G, **Freidlin B**, Gastwirth JL. Using Kullback-Leibler information for model selection when the data-generating model is unknown: application to genetic testing problems. *Statistica Sinica* 14:1021-1036, 2004

32. George SL, **Freidlin B**, Korn EL. Strength of accumulating evidence and data monitoring committee decision making. *Statistics in Medicine* 23:2659-2672, 2004
33. Gastwirth JL, **Freidlin B**. A note on appropriate use of statistical tests of mutation rates from ordered groups. *Genetic Testing* 8:437-440, 2004
34. Zheng G, **Freidlin B**, Li ZH, Gastwirth JL. Genomic control for association studies under various genetic models. *Biometrics* 61:187-193, 2005
35. **Freidlin B**, Korn EL. Testing treatment effects in the presence of competing risks. *Statistics in Medicine* 24:1703-1712, 2005
36. **Freidlin B**, Simon R. An evaluation of randomized discontinuation design. *Journal of Clinical Oncology* 23:5094-5098, 2005
37. Korn EL, Hunsberger S, **Freidlin B**, Smith MA, Abrams JS. Preliminary data release for randomized clinical trials of noninferiority: a new proposal. *Journal of Clinical Oncology* 23:5831-5836, 2005
38. Rubinstein LV, Korn EL, **Freidlin B**, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening Trials. *Journal Of Clinical Oncology* 23:7199-7206, 2005
39. **Freidlin B**, Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. *Clinical Cancer Research* 11:7872-7878, 2005
40. Zheng G, **Freidlin B**, Gastwirth JL. Robust genomic control for association studies. *The American Journal of Human Genetics* 78: 350-356, 2006
41. Korn EL, **Freidlin B**. The likelihood as statistical evidence in multiple comparisons in clinical trials: No free lunch. *Biometrical Journal* 48: 346-355, 2006
42. Korn EL, **Freidlin B**. Conditional power calculations for clinical trials with historical controls. *Statistics in Medicine* 25:2922-2931, 2006
43. **Freidlin B**, Korn EL. Letter to the editor - Testing treatment effects in the presence of competing risks. *Statistics in Medicine* 25:3761-3763, 2006
44. Korn EL, **Freidlin B**. A posterior tale. *Biometrical Journal* 49: 346-50, 2007
45. Jackman, DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borrás AM, **Freidlin B**, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne, PA. Phase II Clinical Trial of Chemotherapy-Naïve Patients

- ≥ 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology* 25:760-6, 2007
46. **Freidlin B**, Korn EL. Release of data from an ongoing randomized clinical trial for sample size adjustment or planning. *Statistics in Medicine* 26:4074-4082, 2007
 47. **Freidlin B**, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded randomized trials. *Journal of Clinical Oncology* 25:2122-6, 2007
 48. Jiang W, **Freidlin B**, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. *Journal of the National Cancer Institute* 99:1036-43, 2007
 49. **Freidlin B**, Korn EL, George SL, Gray R. Randomized clinical trial design for assessing non-inferiority when superiority is expected. *Journal of Clinical Oncology* 25:5019-5023, 2007
 50. Korn EL and **Freidlin B**. A note on controlling the number of false positives. *Biometrics* 64:227-231, 2008
 51. Korn EL, Hunsberger S, **Freidlin B**, Smith MA, Abrams JS. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al. (letter). *Clinical Trials* 5(4):364-5, 2008
 52. Hunsberger S, **Freidlin B**, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. (letter) *Journal of Clinical Oncology* 26(18):3103-4, 2008
 53. **Freidlin B**, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. *Clinical Cancer Research* 14(14):4368-71, 2008
 54. Dodd LE, Korn EL, **Freidlin B**, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? *Journal of Clinical Oncology* 26:3791-6, 2008
 55. **Freidlin B**, Korn EL. Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial. *Journal of Clinical Oncology* 27:629-33, 2009
 56. Korn EL, **Freidlin B**, Mooney M. Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The NCI Cooperative Group Experience 1990-2005. *Journal of Clinical Oncology* 27:1543-4, 2009
 57. **Freidlin B**, Korn EL. Stopping clinical trials early for benefit: impact on

- estimation. *Clinical Trials* 6:119-25, 2009
58. **Freidlin B**, Jiang W, Simon R. The cross-validated adaptive signature design. *Clinical Cancer Research* 16:691-8, 2010
 59. **Freidlin B**, McShane LM, Korn EL. Randomized Clinical Trials With Biomarkers: Design Issues. *Journal of the National Cancer Institute* 102:152-160, 2010
 60. Korn EL, **Freidlin B**, Mooney M. Bias in trials stopped early for benefit. (letter) *Journal of the American Medical Association* 304:157-158, 2010
 61. **Freidlin B**, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. *Clinical Trials* 7:197-208, 2010
 62. Korn EL, **Freidlin B**, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. *Journal of Clinical Oncology* 28:5197-201, 2010
 63. **Freidlin B**, Korn EL. Biomarker-adaptive clinical trial designs. *Pharmacogenomics* 11:1679-1682, 2010
 64. Korn EL, Dodd LE, **Freidlin B**. Measurement error in the timing of events: effect on survival analyses in randomized clinical trials. *Clinical Trials* 7: 626-633, 2010
 65. Korn EL, **Freidlin B**. Causal inference for definitive clinical endpoints in a randomized clinical trial with intervening nonrandomized treatments. *Journal of Clinical Oncology* 28: 3799-3800, 2010
 66. Korn EL, **Freidlin B**. Outcome-adaptive randomization: is it useful? *Journal of Clinical Oncology* 29:771-6, 2011
 67. Korn EL, **Freidlin B**. Inefficacy monitoring procedures in randomized clinical trials: the need to report. *American Journal of Bioethics*. 11: 2-10, 2011
 68. Korn EL, **Freidlin B**. Reply to Y. Yuan et al. *Journal of Clinical Oncology* 29, e393, 2011
 69. Simon RM, **Freidlin B**. Re: Designing a randomized clinical trial to evaluate personalized medicine: A new approach based on risk prediction. *Journal of the National Cancer Institute* 03:445, 2011
 70. Korn EL, **Freidlin B**, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. *Journal of Clinical Oncology* 29:2439-2442, 2011

71. Korn EL, **Freidlin B**, Abrams JS. Reply to M. Buyse et al. *Journal of Clinical Oncology* 29:4720-4721, 2011
72. Dodd LE, Korn EL, **Freidlin B**, Gray R, and Bhattacharya S. An audit strategy for progression-free survival. *Biometrics* 267:1092-1099, 2011
73. Korn EL, **Freidlin B**, Abrams JS and Halabi S. Design issues in randomized phase II/III trials. *Journal of Clinical Oncology* 30:667-671, 2012
74. Korn EL, **Freidlin B** and Abrams JS. Bevacizumab in ovarian cancer (letter). *New England Journal of Medicine* 366:1256, 2012
75. **Freidlin B**, Korn EL. Assessing causal relationships between treatments and clinical outcomes: always read the fine print. *Bone Marrow Transplantation* 47:626-632, 2012
76. **Freidlin B**, McShane LM, Polley M-Y, and Korn EL. Randomized phase II trial designs with biomarkers. *Journal of Clinical Oncology* 30:3304-3309, 2012
77. Korn EL, **Freidlin B**. Methodology for comparative effectiveness research: Potential and limitations. *Journal of Clinical Oncology* 30: 4185-4187, 2012
78. Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, **Freidlin B**, et al: NCI-RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers. *Journal of the National Cancer Institute* 105:11-24, 2013
79. **Freidlin B**, Korn EL. Borrowing Information Across Subgroups: Is It Useful? *Clinical Cancer Research* 19:1326-1334, 2013
80. **Freidlin B**, Korn EL. Adaptive randomization versus interim Monitoring. *Journal of Clinical Oncology* 31:969-970, 2013
81. Korn EL, McShane LM, **Freidlin B**. Statistical challenges in the evaluation of treatments for small patient populations *Science Translational Medicine*, 5 (178), art. no. 178sr3, 2013
82. **Freidlin B**, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and biomarker evaluation. *Journal of Clinical Oncology* 31: 3158-3161, 2013
83. **Freidlin B**, Abrams JS, Korn EL. New challenges for comparative effectiveness in oncology: Choice of primary end points for randomized clinical trials. *Journal of Comparative Effectiveness Research*, 2: 469-481, 2013

84. Dodd LE, Korn EL, **Freidlin B**, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology. *Clinical Trials*, 10:754-760, 2013
85. Polley M-Y, **Freidlin B**, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical considerations for clinical evaluation of predictive biomarkers. *Journal of the National Cancer Institute*, 105:1677-1683, 2013
86. **Freidlin B**, Korn EL. Biomarker enrichment strategies: Matching trial design to biomarker credentials *Nature Reviews Clinical Oncology*, 11: 81-90, 2014
87. **Freidlin B**, Korn EL, Gray R. Marker Sequential Test (MaST) design *Clinical Trials*, 11: 19-27, 2014
88. **Freidlin B**, Korn EL. Transparency in interim monitoring *Journal of Clinical Oncology*, 32:2387-2388, 2014
89. **Freidlin B**, Sun Z, Gray R, Korn EL. Reply to Goteti et al. *Journal of Clinical Oncology* 32: 856, 2014
90. **Freidlin B**, Korn EL. A model too far. *Journal of the National Cancer Institute*, 106(2):djt638, 2014
91. **Freidlin B**, Korn EL. Response to Etzioni and Gulati. *Journal of the National Cancer Institute*, 106(4):dju059, 2014
92. Polley MY, Polley EC, Huang EP, **Freidlin B**, Simon R. Two-stage adaptive cutoff design for building and validating a prognostic biomarker signature. *Statistics in Medicine*, 33:5097-110, 2014
93. Korn EL, Dignam JJ, **Freidlin B**. Assessing treatment benefit with competing risks not affected by the randomized treatment. *Statistics in Medicine*, 34:265-80, 2015
94. Korn EL, **Freidlin B**. Commentary on Hey and Kimmelman. *Clinical Trials*, 12: 122-124, 2015
95. Korn EL. **Freidlin B**. Evaluation of chemoresponse assays as predictive marker. *British Journal of Cancer* 112:621-623, 2015
96. Korn EL. **Freidlin B**. Response to Comment on: Evaluation of chemoresponse assays as predictive marker. *British Journal of Cancer* 112:1978, 2015

97. **Freidlin B**, Little RF, Korn L. Design issues in randomized clinical trials of maintenance therapies. *Journal of the National Cancer Institute* 107(11): djv225, 2015
98. **Freidlin B**, Korn EL, RE: Impact of a biomarker-based strategy on oncology drug development: A meta-analysis of clinical trials leading to FDA approval. (letter) *Journal of the National Cancer Institute* 108:djv430, 2016
99. **Freidlin B**, Othus M, and Korn EL. Information time scales for interim analyses of randomized clinical trials. *Clinical Trials* 13:391-399, 2016
100. Korn EL and **Freidlin B**. Non-factorial analyses of two-by-two factorial trial designs. *Clinical Trials* 13: 651-659, 2016
101. Korn EL, **Freidlin B**. Reader reaction on estimation of treatment effects in all-comers randomized clinical trials with a predictive marker. *Biometrics* 73:706-708, 2017
102. Zhang Q, **Freidlin B**, Korn EL, Halabi S, Mandrekar S, and Dignam JJ. Comparison of futility monitoring guidelines using completed phase III oncology trials. *Clinical Trials* 14:48-58, 2017
103. Little RF, McShane LM, **Freidlin B**. Myeloma minimal residual disease and surrogacy (letter). *JAMA Oncology* doi: 10.1001/jamaoncol.2016.5660, 2017
104. **Freidlin B** and Korn EL. Sample size adjustment designs with time-to-event outcomes: a caution. *Clinical Trials* 14:597-604, 2017
105. **Freidlin B** and Korn EL. Rejoinder to Dr. Mehta. *Clinical Trials* 14:609-610. 2017
106. Korn EL, Othus M, Chen T-T and **Freidlin B**. Assessing treatment efficacy in the subset of responders in a randomized clinical trial. *Annals of Oncology* 28:1640-1647, 2017
107. Korn EL and **Freidlin B**. Adaptive Clinical Trials: Advantages and disadvantages of various adaptive design elements. *Journal of the National Cancer Institute* 109: dlx013, 2017
108. **Freidlin B** and Korn EL. Two-by-two factorial cancer treatment trials: Is sufficient attention being paid to possible interactions? *Journal of the National Cancer Institute* 109:djx146, 2017
109. Korn EL, **Freidlin B**. Quantitative assessment of a prognostic or predictive biomarker panel. *Journal of Biopharmaceutical Statistics* 28:264-281, 2018

110. Korn EL, **Freidlin B**. Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies. *Annals of Oncology* 29:573-577, 2018
111. Korn EL, **Freidlin B**. Surrogate and intermediate endpoints in randomized trials: what's the goal? *Clinical Cancer Research* 24:2239-40, 2018
112. **Freidlin B**, Korn EL, Abrams JS. Bias, operational bias, and generalizability in phase II/III trials. *Journal of Clinical Oncology* 36:1902-04, 2018
113. Korn EL, **Freidlin B**. Interim futility monitoring assessing immune therapies with a potentially delayed treatment effect. *Journal of Clinical Oncology* 36:2444-49, 2018
114. Yee LM, McShane LM, **Freidlin B**, Mooney MM, Korn EL. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials. *Cancer Journal* 25:254-263, 2019
115. Korn EL, Gray RJ, **Freidlin B**. Noninferiority trials with nonadherence to the assigned randomized treatment. *Clinical Trials* 16:673-681, 2019
116. **Freidlin B**, Korn EL. Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis? *Journal of Clinical Oncology* 37:3455-3459, 2019
117. Polley M-YC, Korn EL, **Freidlin B**. Phase III precision medicine clinical trial design that integrates treatment and biomarker evaluation *JCO Precision Oncology* 3:1-9, 2019
118. Foster JC, **Freidlin B**, Kunos CA, Korn EL. Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017. *Journal of the National Cancer Institute* 112:djz193, 2020
119. **Freidlin B**, Allegra CJ, Korn EL. Moving Molecular Profiling to Routine Clinical Practice: A Way Forward? *Journal of the National Cancer Institute* djz240, 2020
120. **Freidlin B**, Korn EL. Reply to H Uno et al and B Huang et al. *Journal of Clinical Oncology* 38: 2003-2004, 2020
121. Foster JC, **Freidlin B**, Korn EL, and Smith M. Evaluation of the contribution of randomized cancer clinical trials evaluating agents without documented single-agent activity. *ESMO Open* 5:e000871, 2020
122. **Freidlin B**, Hu, C, Korn EL. Are restricted mean survival time methods especially useful for Noninferiority Trials? *Clinical Trials* 18:188-196, 2021

123. Dodd LE, **Freidlin B**, and Korn EL. Platform trials – Beware the noncomparable control group. *New England Journal of Medicine* 384:1572-1573, 2021
124. **Freidlin B**, Hu C, and Korn EL. Reply to Quartagno et al. *Clinical Trials* 18:746, 2021
125. **Freidlin B** and Korn EL. A problematic biomarker trial design. *Journal of the National Cancer Institute* 114:187-190, 2022
126. Korn EL and **Freidlin B**. Time trends with response adaptive randomization: the inevitability of inefficiency. *Clinical Trials* doi.org/10.1177/17407745211065762

Book Chapters:

1. Simon R, Dixon D, **Freidlin B**. A Bayesian model for evaluating specificity of treatment effects in clinical trials. *Recent Advances In Clinical Trial Design*, Thall P. editor, Kluwer Academic Publishers, Boston, 1995
2. Simon R, Dixon D, **Freidlin B**. Bayesian subset analysis of a clinical trial for the treatment of HIV infection. *Bayesian Biostatistics*, Berry D and Stangl D. (eds.), Marcel-Dekker, New-York, 1996
3. **Freidlin B**, and Gastwirth JL. The application of change point tests to data occurring in fair hiring cases. *Asymptotic Methods in Probability and Statistics (ICAMPS)*, Szyszkowicz B. editor, Elsevier Science, Amsterdam, 1998
4. Gastwirth JL, **Freidlin B**, Miao W. The Shonubi case as an example of the legal system's failure to appreciate statistical evidence. *Statistical Science in the Courtroom*, Gastwirth JL editor, Springer, New-York, 2000
5. Zheng G, **Freidlin B**, and Gastwirth JL. Comparison of robust test for genetic association using case-control studies. *IMS Lecture Notes-Monograph Series*, 2006
6. Dancey J, **Freidlin B**, and Rubinstein L. Accelerated titration designs. *Statistical Methods in Dose-Finding Studies*, Chevret S. editor, Wiley, New-York, 2006
7. **Freidlin B**. Futility analysis. *Encyclopedia of Clinical Trials*, Wiley, New-York, 2007
8. Korn EL, **Freidlin B**. Interim analysis of phase III trials. *Oncology Clinical Trials*, Kelly and Halabi S (eds.), Demos Medical, New York, 2010
9. McShane LM, Korn EL, **Freidlin B**. Statistical considerations in the development and evaluation of therapeutic biomarkers in cancer. In *Handbook of Therapeutic Biomarkers in Cancer*, Yang, Dancey (eds.), Pan Stanford, Singapore, 2013.
10. **Freidlin B**. Futility analysis. In *Methods and Applications of Statistics in Clinical Trials: Planning, Analysis, and Inferential Methods*. Balakrishnan N editor, Wiley, New York, 2014.
11. Korn EL, **Freidlin B**. Outcome-adaptive randomization in early clinical trials. In *Design and Analysis of Clinical Trials for Predictive Medicine*, Matsui S, Buyse ME and Simon R (eds.), Chapter 7, CRC Press, Boca Raton, FL, 2015
12. **Freidlin B**. and Simon R. Adaptive clinical trial designs with biomarker development and validation In *Design and Analysis of Clinical Trials for*

- Predictive Medicine*, Matsui S, Buyse ME and Simon R (eds.), Chapter 18, CRC Press, Boca Raton, FL, 2015
13. **Freidlin B.** Korn EL. Ethics of outcome adaptive randomization. *Wiley Statistics Reference Online*, Wiley, New York, 2016
 14. Korn EL and **Freidlin B.** Clinical Trial Designs in Oncology. In *Abeloff's Clinical Oncology*, Sixth Edition Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, and Tepper JE (eds.), New York: Elsevier, 2019
 15. **Freidlin B** and Korn EL. Adaptive Phase II trials. *Principles and Practice of Clinical Trials*, S. Piantadosi, C. Meinert (eds.), Springer, New-York, 2020
 16. **Freidlin B** and Korn EL. Futility Analysis. *Wiley StatsRef: Statistics Reference Online*, John Wiley 2021

Book reviews:

Ellenberg SS, Fleming TR, and DeMets DL. *Data Monitoring Committees in Clinical Trials*, 2002; New York: Wiley. *Biometrics*, 59:457-458, 2003